FLRT3, Agonist of ADGRL3, CAS No.rp174021, Agonist of ADGRL3

CAS: rp174021 Cat. No.: rp174021

GRADE & PURITY Moligand™

Specifications

Product Name

FLRT3, Agonist of ADGRL3, CAS No.rp174021

Synonyms

fibronectin-like domain-containing leucine-rich transmembrane protein 3;leucine-rich repeat transmembrane protein FLRT3

Grade

Moligand™

Specifications & Purity

Moligand™

Action Type

AGONIST

Mechanism of action

Agonist of ADGRL3

CAS

rp174021

Molecule Type

Peptide

Product Line

Biological Products

Storage and Shipping

Storage

Room temperature

Associated Targets(Human)

ADGRL3 Tbio Adhesion G protein-coupled receptor L3 (0 Activities)

Discover Target: ADGRL3

Activity Type	Activity Value -log(M)	Mechanism of Action	Activity Reference	Publications (PubMed IDs)

Genetic information

• Alternate Names: fibronectin-like domain-containing leucine-rich transmembrane protein 3;leucine-rich repeat transmembrane protein FLRT3
• Reference:
  • 1. Kinetics and inhibition of recombinant human cystathionine gamma-lyase. Toward the rational control of transsulfuration., The Journal of biological chemistry, Steegborn, C C and 7 more authors.
  • 2. Generation and initial analysis of more than 15,000 full-length human and mouse cDNA sequences., Proceedings of the National Academy of Sciences of the United States of America, Strausberg, Robert L RL and 83 more authors.
  • 3. Genomic basis of cystathioninuria (MIM 219500) revealed by multiple mutations in cystathionine gamma-lyase (CTH)., Human genetics, Wang, Jian J and Hegele, Robert A RA.
  • 4. Cloning and nucleotide sequence of human liver cDNA encoding for cystathionine gamma-lyase., Biochemical and biophysical research communications, Lu, Y Y, O'Dowd, B F BF, Orrego, H H and Israel, Y Y.
  • 5. Single nucleotide polymorphism in CTH associated with variation in plasma homocysteine concentration., Clinical genetics, Wang, J J, Huff, A M AM, Spence, J D JD and Hegele, R A RA.
  • 6. Cystathionine gamma-lyase overexpression inhibits cell proliferation via a H2S-dependent modulation of ERK1/2 phosphorylation and p21Cip/WAK-1., The Journal of biological chemistry, Yang, Guangdong G, Cao, Kun K, Wu, Lingyun L and Wang, Rui R.
  • 7. The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC)., Genome research, Gerhard, Daniela S DS and 115 more authors.
  • 8. Towards a proteome-scale map of the human protein-protein interaction network., Nature, Rual, Jean-François JF and 37 more authors.
  • 9. The DNA sequence and biological annotation of human chromosome 1., Nature, Gregory, S G SG and 178 more authors.
  • 10. Polymorphisms in one-carbon metabolism and trans-sulfuration pathway genes and susceptibility to bladder cancer., International journal of cancer, Moore, Lee E LE and 14 more authors. more
  • 11. Toward a confocal subcellular atlas of the human proteome., Molecular & cellular proteomics : MCP, Barbe, Laurent L and 10 more authors.
  • 12. Kinetic properties of polymorphic variants and pathogenic mutants in human cystathionine gamma-lyase., Biochemistry, Zhu, Weidong W, Lin, Alexander A and Banerjee, Ruma R.
  • 13. Pathway-based evaluation of 380 candidate genes and lung cancer susceptibility suggests the importance of the cell cycle pathway., Carcinogenesis, Hosgood, H Dean HD and 12 more authors.
  • 14. Relationship between cystathionine gamma-lyase gene polymorphism and essential hypertension in Northern Chinese Han population., Chinese medical journal, Li, Yun Y and 8 more authors.
  • 15. Active cystathionine beta-synthase can be expressed in heme-free systems in the presence of metal-substituted porphyrins or a chemical chaperone., The Journal of biological chemistry, Majtan, Tomas T, Singh, Laishram R LR, Wang, Liqun L, Kruger, Warren D WD and Kraus, Jan P JP.
  • 16. MALDI-TOF MS genotyping of polymorphisms related to 1-carbon metabolism using common and mass-modified terminators., Clinical chemistry, Meyer, Klaus K, Fredriksen, Ase A and Ueland, Per Magne PM.
  • 17. Structural basis for the inhibition mechanism of human cystathionine gamma-lyase, an enzyme responsible for the production of H(2)S., The Journal of biological chemistry, Sun, Qingxiang Q and 10 more authors.
  • 18. Oral facial clefts and gene polymorphisms in metabolism of folate/one-carbon and vitamin A: a pathway-wide association study., Genetic epidemiology, Boyles, Abee L AL and 16 more authors.
  • 19. Large-scale proteomics and phosphoproteomics of urinary exosomes., Journal of the American Society of Nephrology : JASN, Gonzales, Patricia A PA and 7 more authors.
  • 20. An association study of 45 folate-related genes in spina bifida: Involvement of cubilin (CUBN) and tRNA aspartic acid methyltransferase 1 (TRDMT1)., Birth defects research. Part A, Clinical and molecular teratology, Franke, Barbara B and 7 more authors.
  • 21. Polymorphisms in innate immunity genes and lung cancer risk in Xuanwei, China., Environmental and molecular mutagenesis, Shen, Min M and 12 more authors.
  • 22. H2S biogenesis by human cystathionine gamma-lyase leads to the novel sulfur metabolites lanthionine and homolanthionine and is responsive to the grade of hyperhomocysteinemia., The Journal of biological chemistry, Chiku, Taurai T and 5 more authors.
  • 23. Variations in folate pathway genes are associated with unexplained female infertility., Fertility and sterility, Altmäe, Signe S and 7 more authors.
  • 24. Bile-acid-activated farnesoid X receptor regulates hydrogen sulfide production and hepatic microcirculation., World journal of gastroenterology, Renga, Barbara B, Mencarelli, Andrea A, Migliorati, Marco M, Distrutti, Eleonora E and Fiorucci, Stefano S.
  • 25. Cystathionine gamma-lyase: Clinical, metabolic, genetic, and structural studies., Molecular genetics and metabolism, Kraus, Jan P JP and 14 more authors.
  • 26. Relative contributions of cystathionine beta-synthase and gamma-cystathionase to H2S biogenesis via alternative trans-sulfuration reactions., The Journal of biological chemistry, Singh, Sangita S, Padovani, Dominique D, Leslie, Rachel A RA, Chiku, Taurai T and Banerjee, Ruma R.
  • 27. PTEN identified as important risk factor of chronic obstructive pulmonary disease., Respiratory medicine, Hosgood, H Dean HD, Menashe, Idan I, He, Xingzhou X, Chanock, Stephen S and Lan, Qing Q.
  • 28. Genetic susceptibility to distinct bladder cancer subphenotypes., European urology, Guey, Lin T LT and 18 more authors.
  • 29. Gene-centric association signals for lipids and apolipoproteins identified via the HumanCVD BeadChip., American journal of human genetics, Talmud, Philippa J PJ and 38 more authors.
  • 30. Integrative predictive model of coronary artery calcification in atherosclerosis., Circulation, McGeachie, Michael M and 13 more authors.
  • 31. Cystathionine beta-synthase 844Ins68 polymorphism is not associated with the levels of homocysteine and cysteine in an Indian population., Biomarkers : biochemical indicators of exposure, response, and susceptibility to chemicals, Kumar, Jitender J, Garg, Gaurav G, Karthikeyan, Ganesan G and Sengupta, Shantanu S.
  • 32. The expression and activity of cystathionine-γ-lyase and 3-mercaptopyruvate sulfurtransferase in human neoplastic cell lines., Amino acids, Jurkowska, Halina H, Placha, Wojciech W, Nagahara, Noriuki N and Wróbel, Maria M.
  • 33. Ancient origin of the CTH alelle carrying the c.200C>T (p.T67I) variant in patients with cystathioninuria., Clinical genetics, Espinós, C C and 8 more authors.
  • 34. Variation at the NFATC2 locus increases the risk of thiazolidinedione-induced edema in the Diabetes REduction Assessment with ramipril and rosiglitazone Medication (DREAM) study., Diabetes care, Bailey, Swneke D SD and 11 more authors.
  • 35. Maternal genes and facial clefts in offspring: a comprehensive search for genetic associations in two population-based cleft studies from Scandinavia., PloS one, Jugessur, Astanand A and 12 more authors.
  • 36. [Expression of cystathionine-γ-lyase/hydrogen sulfide pathway in CVB3-induced myocarditis in mice]., Zhongguo dang dai er ke za zhi = Chinese journal of contemporary pediatrics, Hua, Wang W and 6 more authors.
  • 37. Folate-metabolizing gene variants and pregnancy outcome of IVF., Reproductive biomedicine online, Laanpere, M M and 5 more authors.
  • 38. Specificity protein-1 as a critical regulator of human cystathionine gamma-lyase in smooth muscle cells., The Journal of biological chemistry, Yang, Guangdong G, Pei, Yanxi Y, Teng, Huajian H, Cao, Qiuhui Q and Wang, Rui R.
  • 39. Phylogenetic-based propagation of functional annotations within the Gene Ontology consortium., Briefings in bioinformatics, Gaudet, Pascale P, Livstone, Michael S MS, Lewis, Suzanna E SE and Thomas, Paul D PD.
  • 40. Expression of cystathionine β-synthase and cystathionine γ-lyase in human pregnant myometrium and their roles in the control of uterine contractility., PloS one, You, Xing-Ji XJ and 8 more authors.
  • 41. MicroRNA-21 represses human cystathionine gamma-lyase expression by targeting at specificity protein-1 in smooth muscle cells., Journal of cellular physiology, Yang, Guangdong G, Pei, Yanxi Y, Cao, Qiuhui Q and Wang, Rui R.
  • 42. H2S-Induced sulfhydration of the phosphatase PTP1B and its role in the endoplasmic reticulum stress response., Science signaling, Krishnan, Navasona N, Fu, Cexiong C, Pappin, Darryl J DJ and Tonks, Nicholas K NK.
  • 43. Characterization of hydrogen sulfide and its synthases, cystathionine β-synthase and cystathionine γ-lyase, in human prostatic tissue and cells., Urology, Guo, Hui H and 5 more authors.
  • 44. Sp1 is involved in regulation of cystathionine γ-lyase gene expression and biological function by PI3K/Akt pathway in human hepatocellular carcinoma cell lines., Cellular signalling, Yin, Peng P and 12 more authors.
  • 45. H₂S protects against pressure overload-induced heart failure via upregulation of endothelial nitric oxide synthase., Circulation, Kondo, Kazuhisa K and 14 more authors.
  • 46. Reduced cystathionine γ-lyase and increased miR-21 expression are associated with increased vascular resistance in growth-restricted pregnancies: hydrogen sulfide as a placental vasodilator., The American journal of pathology, Cindrova-Davies, Tereza T and 5 more authors.
  • 47. Dysregulation of hydrogen sulfide producing enzyme cystathionine γ-lyase contributes to maternal hypertension and placental abnormalities in preeclampsia., Circulation, Wang, Keqing K and 14 more authors.
  • 48. Regulation of cystathionine γ-lyase in mammalian cells by hypoxia., Biochemical genetics, Wang, Maoxian M, Guo, Zhanyun Z and Wang, Shilong S.
  • 49. A genome-wide association study of chemotherapy-induced alopecia in breast cancer patients., Breast cancer research : BCR, Chung, Suyoun S and 6 more authors.
  • 50. [Cystathionine γ-lyase]., Postepy higieny i medycyny doswiadczalnej (Online), Jurkowska, Halina H, Kaczor-Kamińska, Marta M, Bronowicka-Adamska, Patrycja P and Wróbel, Maria M.
  • 51. Decreased cystathionine-γ-lyase (CSE) activity in livers of type 1 diabetic rats and peripheral blood mononuclear cells (PBMC) of type 1 diabetic patients., The Journal of biological chemistry, Manna, Prasenjit P, Gungor, Neslihan N, McVie, Robert R and Jain, Sushil K SK.
  • 52. Hydrogen sulfide (H2S)/cystathionine γ-lyase (CSE) pathway contributes to the proliferation of hepatoma cells., Mutation research, Pan, Yan Y and 5 more authors.
  • 53. The cystathionine γ-lyase/hydrogen sulfide system maintains cellular glutathione status., The Biochemical journal, Lee, Zheng-Wei ZW, Low, Yi-Lian YL, Huang, Shufen S, Wang, Tianxiao T and Deng, Lih-Wen LW.
  • 54. The binding site for the transcription factor, NF-κB, on the cystathionine γ-lyase promoter is critical for LPS-induced cystathionine γ-lyase expression., International journal of molecular medicine, Wang, Maoxian M, Guo, Zhanyun Z and Wang, Shilong S.
  • 55. Regulation of cystathionine gamma-lyase/H₂S system and its pathological implication., Frontiers in bioscience (Landmark edition), Zhao, Kexin K, Li, Hongzhu H, Li, Shuangshuang S and Yang, Guangdong G.
  • 56. Dysregulation of hydrogen sulphide metabolism impairs oviductal transport of embryos., Nature communications, Ning, Nannan N and 5 more authors.
  • 57. Wnt/β-catenin signaling induces the transcription of cystathionine-γ-lyase, a stimulator of tumor in colon cancer., Cellular signalling, Fan, Kun K and 7 more authors.
  • 58. miRNA-30 family inhibition protects against cardiac ischemic injury by regulating cystathionine-γ-lyase expression., Antioxidants & redox signaling, Shen, Yaqi Y and 7 more authors.
  • 59. Role of the cystathionine γ lyase/hydrogen sulfide pathway in human melanoma progression., Pigment cell & melanoma research, Panza, Elisabetta E and 11 more authors.
  • 60. A proteome-scale map of the human interactome network., Cell, Rolland, Thomas T and 69 more authors.
  • 61. Neurodegeneration in Huntington's disease involves loss of cystathionine γ-lyase., Cell cycle (Georgetown, Tex.), Paul, Bindu D BD and Snyder, Solomon H SH.
  • 62. The importance of MTHFR, MTR, MTRR and CSE expression levels in Caucasian women with preeclampsia., European journal of obstetrics, gynecology, and reproductive biology, Seremak-Mrozikiewicz, Agnieszka A and 6 more authors.
  • 63. The importance of rs1021737 and rs482843 polymorphisms of cystathionine gamma-lyase in the etiology of preeclampsia in the Caucasian population., Ginekologia polska, Mrozikiewicz, Przemysław M PM and 8 more authors.
  • 64. Cystathionine γ-lyase, a H2S-generating enzyme, is a GPBAR1-regulated gene and contributes to vasodilation caused by secondary bile acids., American journal of physiology. Heart and circulatory physiology, Renga, Barbara B and 9 more authors.
  • 65. Correlation between the cystathionine-γ-lyase (CES) and the severity of peptic ulcer disease., African health sciences, Chen, Xiong X, Wan, Ying-Chun YC, Guo, Tao T, Xu, Can-Xia CX and Wang, Fen F.
  • 66. MPST but not CSE is the primary regulator of hydrogen sulfide production and function in the coronary artery., American journal of physiology. Heart and circulatory physiology, Kuo, Maggie M MM and 10 more authors.
  • 67. Transcriptional Regulation of Cystathionine-γ-Lyase in Endothelial Cells by NADPH Oxidase 4-Dependent Signaling., The Journal of biological chemistry, Mistry, Rajesh K RK and 8 more authors.
  • 68. LPS Up-Regulates Cystathionine γ -Lyase Gene Expression in Primary Human Macrophages via NF-κB/ERK Pathway., Inflammation & allergy drug targets, Badiei, Alireza A, Gieseg, Steven S, Davies, Sian S, Izani Othman, Mohd M and Bhatia, Madhav M.
  • 69. Radiation Exposure Promotes Hepatocarcinoma Cell Invasion through Epithelial Mesenchymal Transition Mediated by H2S/CSE Pathway., Radiation research, Pan, Yan Y, Zhou, Cuiping C, Yuan, Dexiao D, Zhang, Jianghong J and Shao, Chunlin C.
  • 70. Cystathionine γ-lyase(CSE)/hydrogen sulfide system is regulated by miR-216a and influences cholesterol efflux in macrophages via the PI3K/AKT/ABCA1 pathway., Biochemical and biophysical research communications, Gong, Duo D and 15 more authors.
  • 71. MicroRNA-186 promotes macrophage lipid accumulation and secretion of pro-inflammatory cytokines by targeting cystathionine γ-lyase in THP-1 macrophages., Atherosclerosis, Yao, Yan Y and 9 more authors.
  • 72. Cystathionine γ-lyase is expressed in human atherosclerotic plaque microvessels and is involved in micro-angiogenesis., Scientific reports, van den Born, J C JC and 5 more authors.
  • 73. Dichotomous effects of isomeric secondary amines containing an aromatic nitrile and nitro group on human aortic smooth muscle cells via inhibition of cystathionine-γ-lyase., Biochimie, Ji, Yajing Y and 6 more authors.
  • 74. Distinctive expression pattern of cystathionine-β-synthase and cystathionine-γ-lyase identifies mesenchymal stromal cells transition to mineralizing osteoblasts., Journal of cellular physiology, Gambari, Laura L and 6 more authors.
  • 75. Age-Dependent Allergic Asthma Development and Cystathionine Gamma-Lyase Deficiency., Antioxidants & redox signaling, Wang, Peipei P and 6 more authors.
  • 76. Augmented H2S production via cystathionine-beta-synthase upregulation plays a role in pregnancy-associated uterine vasodilation., Biology of reproduction, Sheibani, Lili L and 7 more authors.
  • 77. Total sulfane sulfur bioavailability reflects ethnic and gender disparities in cardiovascular disease., Redox biology, Rajpal, Saurabh S and 12 more authors.
  • 78. Oligo-capping: a simple method to replace the cap structure of eukaryotic mRNAs with oligoribonucleotides., Gene, Maruyama, K K and Sugano, S S.

Application Protocols

Only information from Product Data may be listed here.

• Tested applications, recommended concentrations/dilutions, and positive controls: Not specified for this item; refer to CoA/Spec Sheet.

General research guidance (not item‑specific):

• For biochemical binding assays, start with a 10‑point 3‑fold serial dilution from a top concentration aligned with solubility and assay tolerance (commonly 30–100 µM final), maintain constant vehicle, and include appropriate reference controls.
• For cell‑based phenotypic assays, confirm cytotoxicity windows (e.g., CellTiter‑Glo/Resazurin) before target readouts.

Biological Roles

Context (literature, not item‑specific):

• FLRT3 (Fibronectin Leucine‑Rich Transmembrane protein 3) is a type I transmembrane protein characterized by extracellular leucine‑rich repeat (LRR) motifs and an FNIII domain. It participates in cell adhesion and guidance, acting via homophilic interactions and heterophilic binding to receptors such as UNC5 family members and latrophilins (ADGRL). FLRT3 can function as a guidance cue, influencing cell sorting and tissue patterning during development, and modulates signaling pathways that impact cytoskeletal organization and migration.
• In the nervous system, FLRT3 and its family members contribute to axon guidance and synaptic organization via context‑dependent attractive/repulsive cues. Structural studies of LRR domains inform potential small‑molecule or peptide modulators aimed at disrupting or stabilizing PPI interfaces.

Relevance to this catalog entry:

• A compound labeled “FLRT3” in a small‑molecule library is commonly annotated by target association. Such compounds may be explored as putative modulators of FLRT3‑mediated protein–protein interactions or downstream signaling nodes. Definitive biological activity, potency, and selectivity are not provided here and must be established experimentally with validated assays.

Important caveat:

• No biological activity, mechanism of action, or target engagement data are specified for this item. All use is for research only, and users should design controls to exclude assay interference or off‑target effects.

Buffer Applications

Not typically applicable to an unspecified small‑molecule library member. If you plan to test the compound in biochemical or biophysical assays, choose the buffer system appropriate for your assay and target (example, general guidance only):

• Protein–ligand assays (SPR/BLI/FP): HEPES or PBS at pH 7.2–7.5 with 0.005–0.05% surfactant (e.g., Tween‑20 or P20) to reduce nonspecific binding; include 0.5–2% DMSO to match analyte vehicle.
• Thermal shift (DSF/TSA): 10–50 mM HEPES or phosphate, 100–300 mM NaCl, 1–5 mM DTT/TCEP only if the target requires a reduced environment.
• Enzyme assays: Buffer, salt, divalent cations, and cofactors should match the enzyme’s requirements; maintain constant DMSO across wells.

Item‑specific buffer compatibility and solubility: Not specified for this item; refer to CoA/Spec Sheet and determine empirically.

Green Alternatives

Because the compound’s identity and solvent requirements are not disclosed, green‑chemistry guidance must remain general.

General recommendations (not item‑specific):

• Prefer greener solvents for routine handling where compatible with solubility and assay constraints. For example, replace DMF/DMAC/NMP with safer alternatives like Cyrene or propylene carbonate when feasible; replace dichloromethane/chloroform with ethyl acetate or 2‑MeTHF for extractions or preparative work.
• For stock solutions, DMSO remains standard; consider aqueous cosolvent systems (DMSO:buffer) to reduce neat DMSO volumes at point‑of‑use.
• Minimize waste by adopting miniaturized screening formats (384/1536‑well), acoustic dispensing, and plate recycling workflows.

Illustrative solvent comparison (general):

• 2‑MeTHF vs THF: 2‑MeTHF (bio‑sourced, higher boiling point, lower peroxide tendency) can be a greener choice for extractions and some synthetic steps. THF offers broader historical data but forms peroxides readily.
• EtOAc vs DCM: Ethyl acetate is biodegradable with a better environmental profile; DCM offers higher density for phase separations but carries higher toxicity.

Note: Select solvents only after confirming the compound’s solubility/stability profile from the CoA or empirical screening.

Pharmaceutical Uses

No pharmacopeial or formulation role is provided for this item. This product is designated for research use only.

General considerations for researchers (not item‑specific, non‑clinical):

• Early discovery compounds are sometimes profiled for developability attributes (solubility, permeability, stability) to guide medicinal chemistry. If the structure becomes available, evaluate kinetic solubility (pH 1.2/6.8/7.4), microsomal stability, and basic DMPK properties to inform optimization.
• Excipients, dosage forms, and clinical claims are not applicable here. Do not use this material in humans or animals for therapeutic or diagnostic purposes.

Physical Properties

Item‑specific properties (from Product Data):

• Appearance: Not specified for this item; refer to CoA/Spec Sheet.
• Molecular Weight: Not specified for this item; refer to CoA/Spec Sheet.

Critical physico‑chemical data for lab planning (literature/computed — not available here):

• Melting point, boiling point, density, refractive index, logP/logD, pKa, and aqueous/organic solubility are not provided for this item. Do not infer these values without the structure and lot documentation.

Practical guidance (general, not item‑specific):

• For library compounds, typical formats are DMSO stock solutions (e.g., 10–50 mM) or dry powders in moisture‑barrier vials. If received as a solid and structure is later disclosed, determine solubility empirically in a tiered solvent panel (H2O, PBS, MeOH, EtOH, ACN, DMSO, DMF, IPA, acetone, EtOAc) and record outcomes by visual inspection and UV–vis where applicable.
• For ionizable compounds (if applicable), measure pH‑dependent solubility (shake‑flask across pH 2–10) to support assay development. For lipophilic scaffolds, co‑solvent or cyclodextrin strategies may be required.

Action items:

• Consult the CoA/Spec Sheet for batch‑specific physico‑chemical data and recommended solvent. If unavailable, perform a micro‑scale solubility screen before committing to assay plates.

Quality & Grades

Item‑specific facts (from Product Data):

• Grade/Purity designation: Moligand™.

What this generally signifies (general explanation; not item‑specific specifications):

• Moligand™ is used in catalogs to denote small‑molecule entries curated for ligand‑discovery and screening workflows. Such entries typically emphasize confirmed identity and suitability for biochemical/biophysical assays rather than application‑specific certifications (e.g., HPLC‑grade solvent UV specs, pharma compendial compliance).

How to interpret for your work:

• Identity/Characterization: Expect provision of a CoA/Spec Sheet detailing structure (when disclosed), purity method (e.g., HPLC/UPLC), and, if applicable, salt form and counter‑ion. If purity threshold is critical for your assay, verify the numeric purity and analytical method on the CoA; none is specified in the Product Data here.
• Assay readiness: Many library compounds are supplied as neat solids or DMSO stocks. Confirm water content, residual solvents, and salt/hydrate state on the CoA before quantitative screening (IC50, KD) to avoid potency inflation/deflation.
• Trace contaminants and stabilizers: Not specified for this item; refer to CoA/Spec Sheet. If peroxide or antioxidant stabilizers are relevant, they will be disclosed on the batch documentation.

Documentation:

• For regulated or GLP‑like environments, request batch CoA, analytical traces (chromatogram, NMR/MS if available), and storage/handling notes to support chain‑of‑custody and data integrity.

Reaction & Applications

Item‑specific synthetic/reaction applications: Not specified for this item; refer to CoA/Spec Sheet.

General application context for “Moligand™/library” entries (not item‑specific):

• Biochemical screening: Use as a putative ligand in target‐based assays (e.g., fluorescence polarization, SPR, DSF/TSA, MST) or phenotypic assays. The product name “FLRT3” suggests association with the FLRT3 pathway; confirm the exact structure before drawing SAR conclusions.
• Orthogonal validation: If activity is observed, verify by orthogonal readouts to rule out assay interference (e.g., aggregation, redox cycling, fluorescence quenching). Employ PAINS/REOS filters once the structure is known.
• Mechanistic studies: For targets involving protein–protein interactions (PPIs), consider assays amenable to PPI disruption/ligation (AlphaScreen, TR‑FRET, BLI), and map binding using mutagenesis or domain constructs of the FLRT3 system if applicable.
• Chemical biology: If a functional handle exists (e.g., amine/azide once structure is disclosed), derivatize for pull‑downs or imaging probes with caution to retain affinity.

Practical tips (general):

• Prepare fresh assay plates to minimize DMSO‑induced degradation or water uptake. Control final DMSO to ≤1% unless robustness allows higher.
• Include redox, detergent (e.g., 0.01–0.05% Tween‑20), and colloidal aggregation controls (0.01% Triton X‑100 or 0.05% Pluronic F‑127) as appropriate.

Reaction Conditions

Item‑specific reaction conditions are not applicable because the compound’s structure and reactivity are not disclosed; refer to CoA/Spec Sheet if synthetic details are provided.

General guidance for handling small‑molecule library solids/solutions (not item‑specific):

• Weighing and dissolution: Use an analytical balance in a low‑humidity environment. Dissolve initially in dry DMSO to a standard concentration (e.g., 10 mM), then dilute into assay buffer while maintaining constant DMSO across controls.
• Stability checks: Perform short‑term stability tests (room temperature/4 °C, light vs dark) by LC–UV/LC–MS to confirm that the working solution remains intact over the assay timeframe.
• Plate handling: Use acoustic‑compatible DMSO stocks when possible; seal plates to minimize evaporation and edge effects. Equilibrate plates to assay temperature before dispensing to reduce precipitation.

Safety & Handling

Item‑specific safety data (from Product Data):

• GHS Signal Word: Not specified for this item; refer to SDS.
• H‑Statements / GHS Classification / Pictograms: Not specified for this item; refer to SDS.
• Storage Conditions: Room temperature (per Product Data).

General laboratory precautions (defer to SDS as authoritative):

• Handle unknown research chemicals in a fume hood with standard PPE: lab coat, safety glasses, and appropriate chemically resistant gloves (e.g., nitrile). Avoid inhalation of dusts/aerosols and skin contact. Wash thoroughly after handling.
• Prevent cross‑contamination of screening libraries by using clean tips, septum‑sealed vials, and aliquoting to avoid repeated freeze–thaw (if in solution).
• Incompatibilities are structure‑dependent. Until identity is confirmed, avoid strong oxidizers/reductants, strong acids/bases, and reactive metals. Keep away from ignition sources.

First‑aid overview (general):

• Eye/skin contact: Rinse with water for ≥15 minutes; remove contaminated clothing. Seek medical attention if irritation persists.
• Inhalation: Move to fresh air; monitor for respiratory symptoms; seek medical attention as needed.
• Ingestion: Rinse mouth; do not induce vomiting unless directed by medical personnel.

Waste and spill response (general):

• Absorb small spills with inert material; collect in a sealed container for hazardous waste disposal according to institutional and local regulations.

Note: Always consult the product’s SDS and CoA for lot‑specific hazards and handling instructions.

Solvent Selection

Item‑specific solvent guidance: Not specified for this item; refer to CoA/Spec Sheet.

General strategy for library compounds (not item‑specific):

• Primary solvent: DMSO is the default for small‑molecule libraries due to broad solubilizing power and assay compatibility up to 0.1–1% v/v in many biochemical and cell‑based systems.
• Solubility screening: Evaluate a graded panel (water/PBS, MeOH, EtOH, ACN, DMF, DMSO, IPA, acetone, EtOAc). Start with 10 mM target stock; sonicate and gently heat (≤40 °C) if permitted.
• pH adjustment: For ionizable compounds, prepare buffered stocks near pKa ±1 to improve solubility; avoid high ionic strengths that can perturb biophysical assays.
• Volatility/adsorption: For hydrophobic compounds, minimize adsorption losses by using low‑binding plastics or silanized glass; consider co‑solvent systems (DMSO:H2O, DMSO:PEG400:H2O) within assay tolerance.

Comparison note (general):

• DMSO vs DMF: DMSO is less volatile and more biocompatible; DMF can be more aggressive and hygroscopic. Prefer DMSO unless specific assay constraints dictate otherwise.

Storage & Reconstitution

Item‑specific facts (from Product Data):

• Storage Conditions: Room temperature.
• Shipped In: Not specified for this item; refer to CoA/Spec Sheet.
• Appearance/format: Not specified for this item; refer to CoA/Spec Sheet.

General guidance (not item‑specific):

• If supplied as a solid: Store tightly capped in a dry, inert atmosphere away from light. Upon first use, prepare single‑use aliquots of stock solutions (e.g., 10–50 mM in dry DMSO) to minimize repeated opening.
• If supplied as a DMSO solution: Keep vials tightly sealed; minimize headspace to reduce moisture uptake. For long studies, consider storing working stocks at 4 °C and master stocks at −20 °C, and avoid repeated freeze–thaw cycles by aliquoting.
• Reconstitution: Use an anhydrous, assay‑compatible solvent. Vortex/sonicate as needed; filter (0.22 µm PTFE) if particulate remains and filtration is compatible with the compound.

Always defer to the CoA/Spec Sheet for lot‑specific instructions, including exact solvent recommendations, concentration limits, and stability/shelf‑life.

Structure & Identity

Overview: This listing (SKU rp174021) is annotated as FLRT3 within a small‑molecule/compound library context (Moligand™). Item‑specific structural identifiers are not provided in the Product Data.

Item‑specific facts (from Product Data):

• Product Name: FLRT3
• CAS: rp174021 (catalog placeholder)
• Grade: Moligand™
• Molecular formula: Not specified for this item; refer to CoA/Spec Sheet.
• Molecular weight: Not specified for this item; refer to CoA/Spec Sheet.
• SMILES: Not specified for this item; refer to CoA/Spec Sheet.
• InChIKey: Not specified for this item; refer to CoA/Spec Sheet.

General/literature context (not item‑specific):

• FLRT3 commonly refers to Fibronectin Leucine‑Rich Transmembrane protein 3, a mammalian type‑I single‑pass transmembrane protein containing LRR motifs and an extracellular fibronectin type III (FNIII) domain. In chemical library annotations, “FLRT3” typically denotes target association (e.g., putative modulators of FLRT3 signaling or protein–protein interactions), not the structure of the small molecule itself.

Implications for users:

• Without a molecular structure, cheminformatics identifiers (SMILES, InChIKey), stereochemistry, and functional group annotations cannot be provided for this item. Obtain the CoA/Spec Sheet for definitive identity, batch characterization, and to enable database registration (ELN/LIMS).

Synthetic Utility

This section typically discusses functional‑group reactivity for a defined molecule. Because no structure or functional groups are provided for this item, synthetic utility cannot be described.

General note for library compounds (not item‑specific):

• If the compound structure is disclosed and contains common handles (e.g., amines, carboxylates, halides, alkynes/azides), it may be derivatized for probe development (biotinylation, fluorophore tagging) or immobilization on resins for chemoproteomics. Any such modifications should be guided by SAR to avoid abolishing activity.
• For scale‑up or re‑synthesis, request a building‑block proposal and synthetic route once the structure is available; pay attention to stereochemical integrity and polymorph/salt form control.

Target Specificity

Only information from Product Data may be listed here.

• Target/antigen, epitope mapping, species reactivity, clone/isotype: Not specified for this item; refer to CoA/Spec Sheet.

Note: The product name “FLRT3” suggests target association in a library context, but no item‑specific binding data, selectivity, or off‑target profile is provided.

Frequently Asked Questions

How should this product be stored?

Store at room temperature.

What are the CAS number, molecular formula and molecular weight?

The CAS Number is rp174021.

What is Moligand??

Moligand? is one of Aladdin Scientific's premium product lines, formulated for high-purity applications across multiple workflows. Compared to standard grades in the same workflow, Moligand? products typically offer tighter specifications, more rigorous QC, and stronger lot-to-lot consistency.

What documentation is provided?

Available product documentation, including Certificates of Analysis (COA), Safety Data Sheets (SDS), and specification sheets, is shown in the product document area. Document availability and access follow the current site policy.